Amruta Khandekar

Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments

Jan 12 2022

The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.

Compass Health recalls nearly 105,000 bed rails after death reports - U.S. regulator

Dec 22 2021

Consumer medical products maker Compass Health Brands is voluntarily recalling about 104,900 of its bed rails after receiving reports of three deaths associated with some of the products, the U.S. Consumer Product Safety Commission (CPSC) said on Wednesday.

Biogen halves price of Alzheimer's drug to $28,200

Dec 20 2021

(Reuters) -Biogen Inc on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.

Employers' health insurance costs surge in 2021 as elective procedures resume - survey

Dec 13 2021

Health insurance costs for employers rose the most in over a decade this year as Americans resumed non-urgent procedures delayed earlier due to the COVID-19 pandemic, according to a survey published on Monday.

UPDATE 2-Biohaven's migraine therapy shows rapid pain relief in late-stage study

Dec 06 2021

Dec 6 Biohaven Pharmaceutical's intranasal spray to treat migraine helped relieve pain in as early as 15 minutes and met the main goals in a late-stage study, paving the way for the company to file for approval in the United States next year.

Health insurer Cigna hints at easing COVID-19 pain, backs profit goal

Nov 04 2021

(Reuters) -Cigna Corp on Thursday joined rival U.S. health insurers in signaling a lower hit from costs related to COVID-19 next year and maintained its target of at least 10% earnings growth over a newly raised 2021 adjusted profit estimate.

CVS Health sees 2022 profit meeting Street estimates as COVID-19 costs subside

Nov 03 2021

(Reuters) -CVS Health Corp on Wednesday said its adjusted profit target for 2022 should largely meet Wall Street estimates, as it expects volatile medical costs in its health insurance unit to stabilize after the COVID-19 crisis drove them up this year.

Thermo Fisher set to benefit from demand for testing kits, vaccines

Oct 26 2021

Thermo Fisher Scientific Inc's third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said.

Roche's implant for chronic eye disorder wins U.S. approval

Oct 22 2021

(Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments.

UPDATE 3-Canadian National Railway CEO to retire following investor pressure

Oct 19 2021

Oct 19 Canadian National Railway (CN) said on Tuesday Chief Executive Officer Jean-Jacques Ruest will retire at the end of January, following investor demands for his exit after the railroad operator's failed bid for Kansas City Southern.

World News